AM-Pharma is a Dutch clinical stage biopharmaceutical company developing a treatment for acute kidney injury (AKI) that could be lifesaving. The Company does not produce face masks or other medical equipment.
AM-Pharma is backed by a strong syndicate of international investors, including Venture Capital Funds and Corporate Venture Funds. To date, the company has raised over €195 million in equity and debt.
In July 2019 the Company raised €116 million from a European syndicate of investors.
Previously, a Series D funding round was completed in 2011 that totaled €29.2 million, with an additional €12.2 million was raised in 2014.
In addition, the Dutch Ministry of Economic Affairs (Netherlands Enterprise Agency – RVO) granted AM-Pharma non-dilutive financing.
The Company’s main investors include:
